Banque Cantonale Vaudoise Sells 4,596 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Banque Cantonale Vaudoise cut its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 37.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,779 shares of the medical research company's stock after selling 4,596 shares during the quarter. Banque Cantonale Vaudoise's holdings in IQVIA were worth $1,844,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new stake in IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp acquired a new position in IQVIA during the third quarter worth $28,000. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the second quarter worth $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 1.6 %

Shares of IQV opened at $194.38 on Thursday. The business's 50-day moving average price is $224.22 and its 200-day moving average price is $227.56. The stock has a market cap of $35.28 billion, a PE ratio of 25.51, a P/E/G ratio of 1.97 and a beta of 1.51. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Ratings Changes

Several equities research analysts have commented on IQV shares. JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a "buy" rating and a $276.00 price target for the company. StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a research note on Wednesday. Barclays cut their price target on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Finally, BTIG Research decreased their target price on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $256.50.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the company's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company's stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.